Chemomab halves planned post-merger share count to 5,000,000 in Scipher deal

• Chemomab Therapeutics amended its merger agreement on October 16, 2026, reducing the combined company’s planned post-closing shares from 10,000,000 to 5,000,000.
• The amendment leaves transaction consideration, economic value and relative ownership allocations unchanged.
• The planned merger with Scipher Medicine includes redomiciliation to the U.S., with both businesses held by Snowdrift Parent.
• Contingent value rights holders will receive quarterly milestone status reports within 45 days of quarter-end under revised terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004796), on October 19, 2026, and is solely responsible for the information contained therein.